SOURCE: Immune Pharmaceuticals

Immune Pharmaceuticals

December 09, 2014 11:12 ET

CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014

Live Interview Airs on The Trader's Network Radio Show, Hosted by Michael Yorba, 9:00pm ET/6:00pm PT/8:00pm CT

NEW YORK, NY--(Marketwired - Dec 9, 2014) - Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, announced today that CEO Daniel Teper will be interviewed live tomorrow by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Teper will discuss the company's lead product candidate, Bertilimumab, which is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.

Date: December 9, 2014
Start Time: 9:00pm ET | 6:00pm PT | 8:00pm CDT (U.S.)
Network: Clear Channel - iHeart Media
Station: DFW 1190AM
KFXR Show: The Traders Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Immune Pharmaceuticals, Inc.: IMMUNE Pharmaceuticals, Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. IMMUNE licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) (OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive worldwide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca. IMMUNE's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, Crolibulin, a small molecule in Phase II in collaboration with the National Cancer Institute, and Amiket™, a Neuropathic Pain drug candidate ready for Phase III. Amiket has received Orphan Drug Designation for Post Herpetic Neuralgia. For more information, visit http://www.IMMUNEPharmaceuticals.com.

About Clear Channel: Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show: For the past six years "The Traders Network Show" has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am - 7:30am and 2pm - 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It's a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow's ideas today" on iHeart Radio and Clear Channel's The Traders Network Show. To inquire about being a guest on this show please contact "1800PublicRelations" at www.1800pr.com.

Contact Information